Latest Content

Chatbots risk validating suicidal thoughts, highlighting the urgent need for ethical programming to prioritize user safety and human connection.

Explore the emerging field of spiritual psychiatry, addressing the intersection of mental health, ethics, and personal meaning in patient care.

Silo Pharma partners with Allucent to advance SPC-15, a novel treatment for PTSD, aiming for FDA approval and addressing unmet patient needs.

Learn more about the prevalence and implications of psychotropic polypharmacy in treatment-resistant schizophrenia.

Recent studies suggest lithium may effectively prevent cognitive decline and Alzheimer disease, challenging the dominance of lecanemab in early dementia treatment.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

Explore the transformative potential of futures thinking in mental health, offering innovative frameworks to navigate uncertainty and enhance agency.

Explore the evolving role of lamotrigine in treating bipolar depression, highlighting its benefits, risks, and recent clinical guidelines.

New analysis reveals that negative symptoms and stimulant use may predict positive responses to Cobenfy in schizophrenia treatment.

Iclepertin shows no significant cognitive improvement in schizophrenia patients despite good tolerability, highlighting challenges in treating cognitive impairment.

EXCLUSIVE: Check out this recap on the approval of lumateperone (Caplyta) for major depressive disorder.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.

"Without a father to guide me north, your poems were a compass pointing toward a world where doctors can be poets..."